Abstract
Several studies of canine spontaneous mast cell tumours have described mutations in the c-kit proto-oncogene. These mutations produce a constitutively activated product and have been suggested to play a role in the malignant transformation of mast cells. We hypothesize that the selective tyrosine kinase inhibitor imatinib mesylate inhibits signal transduction and induces apoptosis when tested in cutaneous canine mast cell tumour samples positive for mutation in c-kit exon 11. Three-dimensional ex vivo cultures of canine grade II mast cell tumour treated with STI-571 at 48, 72, and 96 h and tested for signal transduction and apoptosis using appropriate assays were used. There was a progressive and significant increase in caspase-3 and TUNEL-positive mast cells compared to the untreated cultures. Additionally, a concurrent reduced expression of Ki67 and BCL-2 was observed. Furthermore, the treated cultures showed a marked reduction of Kit expression. Our results demonstrate that STI-571 induces Caspase-dependent apoptosis in a canine neoplastic mast cells possessing mutations in c-kit exon 11.
Similar content being viewed by others
References
Barzanti F, Zoli W, Susino MD, Ricotti L, Tesei A, Papa S, Reno F, Amadori D (2001) Simultaneous determination of apoptosis and surface antigen expression in tumor adherent cells. J Biol Regul Homeost Agents 15:359–365
Bennett MH, Wilson GD, Dische S, Saunders MI, Martindale CA, Robinson BM, O’Halloran AE, Leslie MD, Laing JH (1992) Tumour proliferation assessed by combined histological and flow cytometric analysis: Implications for therapy in squamous cell carcinoma in the head and neck. Br J Cancer 65:870–878
Demetri GD, Von Mehren M, Blanke CD, Van Den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480
Dixon SC, Soriano BJ, Lush RM, Borner MM, Figg WD (1997) Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target. Ann Pharmacother 31:76–82
Downing S, Chien MB, Kaas PH, Moore PE, London CA (2002) Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 63:1718–1723
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J M 344:1038–1042
Fain O, Stirnemann J, Eclache V, Barete S, Casassus P, Hermine O, Lorholary O (2005) Systemic mastocytosis. Presse Med 34:681–687
Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Sillaber C, Willmann M, Valent P (2007) Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol 35:1510–1521
Goldschmidt MH, Hendrick MJ (2002) Tumors of the skin and soft tissue. In: Meuten DJ (ed) Tumors in domestic animals, 4th edn. Blackwell, Ames, pp 105–107
Gore SD, Weng LJ, Burke PJ (1993) Validation of flow-cytometric determination of Ki67 expression as a measure of growth factor response in acute myelogenous leukemia. Exp Hematol 21:1702–1708
Gown A, Willingham MC (2002) Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem 50:449–454
Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A, Hermine O (2008) Mastinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 22:1301–1309
Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, Kato R, Kobayashi T, Fujita M, Fujino Y, Setoguchi A, Ono K, Washizu T, Bonkobara M (2008) Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med 22:985–988
Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153–164
Kiupel M, Webster JD, Kaneene JB, Miller R, Yuzbasiyan-Gurkan V (2004) The Use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Vet Path 41:371–377
Li N, Margolis LB, Hoffman RM (1991) Skin toxicity determined in vitro by three-dimensional, native-state histoculture. Proc Natl Acad Sci USA 88:1908–1912
London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN (1999) Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 27:689–697
Michels GM, Knapp DW, DeNicola DB, Glickman N, Bonney P (2002) Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases. J Am Anim Hosp Assoc 38:458–466
Morin PJ (2003) Drug resistance and the microenvironment: nature and nurture. Review. Drug Resist Updat 6:169–172
Nakamura T, Kato Y, Fuji H, Horiuchi T, Chiba Y, Tanaka K (2003) E-cadherin-dependent intercellular adhesion enhances chemoresistance. Int J Mol Med 12:693–700
Nocka K, Buck J, Levi E, Besmer P (1990) Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO J 9:3287–3294
Nocka K, Majumder S, Chabot B, Ray P, Cervone M, Bernstein A, Besmer P (1989) Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice—evidence for an impaired c-kit kinase in mutant mice. Genes Dev 3:816–826
Patnaik AK, Ehler WJ, MacEwen EG (1984) Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Path 21:469–474
Qiu FH, Ray P, Brown K, Barker PE, Jhanwer S, Ruddle FH, Besmer P (1988) Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family—oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 7:1003–1011
Rahmani M, Reese E, Dai Y, Bauer C, Kramer LB, Huang M, Jove R, Dent P, Grant S (2005) Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol Pharmacol 67:1166–1176
Reguera MJ, Rabanal RM, Puigdemont A, Ferrer L (2000) Canine mast cell tumors express stem cell factor receptor. Am J Dermatopathol 22:49–54
Resendes AR, Majo N, Segales J, Espadamala J, Mateu E, Chianini F, Nofrarias M, Domingo M (2004) Apoptosis in normal lymphoid organs from healthy normal, conventional pigs at different ages detected by TUNEL and cleaved caspase-3 immunohistochemistry in paraffin-embedded tissues. Vet Immunol Immunopathol 99:203–213
Simoes JPC, Schoning P (1994) Canine mast cell tumors: a comparison of staining techniques. J Vet Diagn Invest 6:458–465
Strasser A, Harris AW, Huang DC, Krammer PH, Cory S (1995) Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 14:6136–6147
Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O’Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New Engl J Med 354:2531–2541
Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science 281:1312–1316
Truong T, Sun G, Doorly M, Wang JY, Schwartz MA (2003) Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl. Proc Natl Acad Sci USA 100:10281–10286
Tsai M, Takeishi T, Thompson H, Langley KE, Zsebo KM, Metcalfe DD, Geissler EN, Galli SJ (1991) Induction of mast cell proliferation, maturation and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci USA 88:6382–6386
Vail DM (1994) Mast cell tumors. In: Withrow SJ, MacEwen EG (eds) Small animal clinical oncology, 2nd edn. WB Saunders, Philadelphia, p 192
Van Etten RA (2004) Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 1:21–28
Yee NS, Paek I, Besmer P (1994) Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of white spotting and steel mutant mice. J Exp Med 179:1777–1787
Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA (2005) The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43–9006. Oncogene 24:6861–6869
Zemke D, Yamini B, Yuzbasiyan-Gurkan V (2002) Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Path 39:529–535
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rossi, G., Bertani, C., Mari, S. et al. Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis. Vet Res Commun 37, 101–108 (2013). https://doi.org/10.1007/s11259-013-9550-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11259-013-9550-5